Dr Phil Boyd

Dr Phil Boyd

Chief Financial Officer

Dr Phil Boyd was CFO of Syntaxin Ltd from 2007 through to the acquisition by Ipsen in July 2013, and CFO of Tiziana Lifesciences plc (AIM: TILS) from 2014 to 2015. Prior to Syntaxin he was UK Finance Director of Evotec AG (2001-2007) and Cambridge Discovery Chemistry (1999-2001). He currently serves as CFO with Enterprise Therapeutics and Oxford BioDynamics, and as a Non-Executive Director with OBN (UK) Ltd. He has a BSc in Biotechnology and a PhD in Genetics from University of Leeds, and is a qualified management accountant (ACMA).

Meet the teams